Portfolio company
Omeicos Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
2 investors
Sectors
About
The company develops synthetic lipid mediators to treat patients with cardiovascular, ophthalmic and primary mitochondrial diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Omthera Pharmaceuticals
This biopharmaceutical company develops omega-3 fatty acid therapies to treat patients with dyslipidemia and high triglyceride levels.
Lime Therapeutics
The company develops lipid-targeting small-molecule medicines for patients with cancer, cardiometabolic diseases, and neurodegenerative disorders.
MitoRx Therapeutics
MitoRx Therapeutics develops small-molecule therapies restoring mitochondrial health to treat patients with high-risk obesity and degenerative diseases.
Cardior
This company develops RNA-based therapeutics designed to prevent, repair and reverse heart diseases for patients with cardiac dysfunctions.
Mighty Therapeutics
This company develops mitochondrial-targeted therapies for patients with rare genetic conditions like Barth syndrome and common age-related diseases.
OMass Therapeutics
This company develops small molecule therapeutics for patients with immunological and rare diseases using a proprietary native mass spectrometry platform.
Rivus Pharmaceuticals
The company develops oral small-molecule medicines for patients with obesity and associated cardiometabolic diseases including heart failure and type 2 diabetes.
Brano Therapeutics
This company develops small-molecule inhibitors to treat heart failure and metabolic dysfunction for patients with cardiovascular diseases.